U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Revolution Medicines announced that the U.S. Food and Drug Administration has granted approval for RASONQUE (daraxonrasib), described as the first broad RAS-targeted medicine cleared for metastatic pancreatic cancer. The company's release, distributed via GlobeNewswire, did not include additional efficacy data, pricing, or launch timing details beyond the approval announcement itself, framing the news primarily around the regulatory milestone and the drug's positioning as a first-in-class therapy.

The approval directly concerns Revolution Medicines, a clinical-stage-turned-commercial biotech that has built its pipeline around RAS-pathway inhibitors, a target long considered difficult to drug. Pancreatic cancer, particularly metastatic disease, carries poor survival rates and limited treatment options, and RAS mutations are present in a large share of pancreatic tumors, making a broad RAS-targeted approach potentially applicable to a wide patient population rather than a narrow genetically-defined subset.

What to watch next includes the company's commercial launch plans, pricing disclosure, payer coverage decisions, and any post-approval data on real-world uptake among oncologists treating metastatic pancreatic cancer. Analysts will also look for guidance on peak sales potential and whether the label supports use earlier in treatment lines or in combination regimens, none of which was addressed in this release.